Soleno Therapeutics, Inc.
SLNO
$43.42
-$0.33-0.75%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 652.53% | 89.24% | 21.81% | 26.93% | -250.58% |
| Total Depreciation and Amortization | 0.00% | -0.40% | 0.20% | 0.60% | 1.21% |
| Total Amortization of Deferred Charges | 0.00% | 12.50% | -- | -- | -- |
| Total Other Non-Cash Items | 3.69% | -40.67% | -41.60% | -48.13% | 618.12% |
| Change in Net Operating Assets | 135.59% | -189.76% | -343.62% | -52.68% | 236.35% |
| Cash from Operations | 444.65% | 61.50% | -36.52% | -60.73% | 15.44% |
| Capital Expenditure | 88.89% | -80.00% | 37.50% | 95.81% | -2,287.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,056.62% | -134.46% | 255.63% | 52.47% | 103.50% |
| Cash from Investing | -1,055.31% | -134.51% | 256.00% | 59.48% | 103.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,270.92% | 384.76% | -54.29% | 215.38% | -98.51% |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -187.10% | -- | -- | -- |
| Cash from Financing | 1,290.49% | 387.54% | -94.36% | 2,408.26% | -98.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,620.17% | 26.72% | -116.69% | 558.89% | -160.74% |